Eisai Co. (ESAIY) and Biogen (BIIB) announced that Eisai has completed the rolling submission of the Supplemental Biologics License Application to the U.S. FDA for Leqembi Iqlik as a weekly starting dose after the FDA granted Fast Track Status. Leqembi is indicated for the treatment of Alzheimer’s disease in patients with Mild Cognitive Impairment or mild dementia stage of disease. Upon acceptance of the sBLA, the FDA will set a Prescription Drug User Fee Act action date.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen’s Strategic Advantage: Buy Rating Amid Competitive Shifts and Promising Pipeline Developments
- Video: Biogen up after Novo weight-loss drug fails to slow Alzheimer’s progress
- Biogen up 4% after Novo Alzheimer’s drug trial misses key target
- Biogen, Dayra Therapeutics enter research collaboration
- Biogen price target raised to $157 from $118 at Piper Sandler